Haisi Gene Technology Completes RMB 220 Million Series A Funding Round to Advance Multiplex Nucleic Acid Testing Solutions

VCBeat (WeChat: vcbeat) has learned that on December 1, 2020, Ningbo Health Gene Technologies Co., Ltd. (“Health Gene Tech”), a provider of multiplex nucleic acid testing solutions, announced the completion of its RMB 220 million Series A financing round. The round was led by Qiming Venture Partners, with participation from DFO Capital, Boyuan Capital, Jingxu Venture Capital, and Lanhu Capital.

The funds from this round of financing will be primarily used for Health Gene Technologies' exploration of new technologies, R&D investment in new product development, and team and business expansion.

Ningbo Health Gene Technologies Co., Ltd. was established in August 2011 and is dedicated to researching and developing comprehensive multiplex nucleic acid testing solutions that feature independent intellectual property rights, align with clinical application scenarios, and deliver exceptional user experience. In recent years, adhering to a clinical-need-oriented approach and grounded in independent R&D and core proprietary technologies, the company has launched multiple industry-leading products, filling gaps in the market.

Ningbo Health Gene Technologies Co.,Ltd. focuses on the development of two core business areas: clinical diagnostics and forensic science. It currently offers three major product lines: molecular diagnostic reagents for clinical diagnostics, nucleic acid testing instruments, and DNA testing reagents for forensic science.

In the field of clinical diagnostics, Ningbo Health Gene Technologies Co., Ltd. has launched a human papillomavirus (HPV) genotyping assay kit targeting the E6/E7 oncogenes as detection sites, becoming the world’s first product of its kind.

The company’s flagship product—the Ruisibei Multiplex Detection Kit for 13 Respiratory Pathogens—is the most comprehensive multiplex nucleic acid detection kit for respiratory pathogens approved in China. When used in conjunction with the T400 Sanger Sequencer, the first domestically produced model launched in 2020, it enables simultaneous detection of multiple pathogens. This provides an effective tool for the clinical diagnosis of acute respiratory infections and the differential diagnosis of COVID-19, thereby helping to mitigate the risk of co-circulation of influenza, SARS-CoV-2, and other respiratory viruses during the first autumn-winter season under the COVID-19 pandemic.

In the field of forensic science, Health Gene Technologies has become one of the largest domestic suppliers of forensic DNA testing reagents. In 2020, it launched its distinctive solid-sphere forensic DNA case-testing reagents, leading the industry’s technological development trends.

Mr. Yu Ding, Chairman and General Manager of Health Gene Technologies“Over the past decade since its establishment, Health Gene Technologies has been committed to independent innovation, launching a series of distinctive products that have gained market recognition. Today, with the addition of investors, our technology and brand are entering a new stage of development. We will further expand our product portfolios for multiplex nucleic acid testing of pathogens and forensic technologies, and invest in the development of an automated, high-throughput, integrated instrument platform. This will enable us to deliver a superior user experience to our customers and provide more valuable solutions to the market.”

Mr. Hu Xubo, Managing Partner of Qiming Venture Partnersstated, “We are delighted to co-invest in Ningbo Health Gene Technologies alongside other investors. Ningbo Health Gene Technologies focuses on the nucleic acid testing market, leveraging independent innovation as its core competency to continuously develop and deliver high-performance diagnostic products that address medical and clinical needs. We will continue to support the company and its team in maintaining their focus on product development and internationalization, enhancing clinical solution capabilities, and driving the company to become an industry leader.”